Biora Therapeutics, Inc. (NASDAQ:BIORQ) — Market Cap & Net Worth
Market Cap & Net Worth: Biora Therapeutics, Inc. (BIORQ)
Biora Therapeutics, Inc. (NASDAQ:BIORQ) has a market capitalization of $994.99K ($994.99K) as of September 20, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #30691 globally and #6234 in its home market, demonstrating a 219900.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biora Therapeutics, Inc.'s stock price $0.22 by its total outstanding shares 4522702 (4.52 Million). Also see Biora Therapeutics, Inc. asset portfolio for a full breakdown of the balance sheet.
Biora Therapeutics, Inc. Market Cap History: 2026 to 2026
Biora Therapeutics, Inc.'s market capitalization history from 2026 to 2026. Data shows growth from $994.99K to $994.99K (0.00% CAGR). Also see Biora Therapeutics, Inc. (BIORQ) cash flow conversion for how efficiently the company converts equity into cash flow.
Biora Therapeutics, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biora Therapeutics, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check BIORQ stock price and chart for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of BIORQ by Market Capitalization
Companies near Biora Therapeutics, Inc. in the global market cap rankings as of September 20, 2026. Explore BIORQ shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Key companies related to Biora Therapeutics, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
Biora Therapeutics, Inc. Historical Marketcap From 2026 to 2026
Between 2026 and today, Biora Therapeutics, Inc.'s market cap moved from $994.99K to $ 994.99K, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $994.99K | -- |
End of Day Market Cap According to Different Sources
On Sep 20th, 2026 the market cap of Biora Therapeutics, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $994.99K USD |
| MoneyControl | $994.99K USD |
| MarketWatch | $994.99K USD |
| marketcap.company | $994.99K USD |
| Reuters | $994.99K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Biora Therapeutics, Inc.
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-fre… Read more